EGFR and small cell lung carcinoma: However, despite advances in therapy, acquired resistance inevitably occurs, including EGFR-dependent resistance (6–10%), MET and HER2 amplifications (8–17%), small cell lung cancer (SCLC), and squamous cell carcinoma (SCC) transformation (15%), and others [63].